Literature DB >> 21771207

The natural history of mild haemophilia: a 30-year single centre experience.

A Tagliaferri1, C Di Perna, F Riccardi, C Pattacini, G F Rivolta, M Franchini.   

Abstract

Although up to 50% of all haemophilic patients followed at haemophilia treatment centres (HTCs) are affected by a mild factor VIII (FVIII) or factor IX (FIX) defect, published data regarding the natural history of these disorders are scarce. To fill this lack of information, a retrospective single centre study was conducted. All cases with mild haemophilia (75 A and 7 B) followed at the regional reference HTC of Parma were evaluated. The patients' median age at diagnosis was 11.5 years and their median age at first bleeding was 5.5 years; 95% of patients had a history of haemorrhagic problems during their life. Twenty-three percent of patients were infected by HCV, and none by HIV. Genetic analysis was performed in 80 patients (97% haemophilia A and 100% haemophilia B) and 21 different mutations were characterized. Eleven percent of patients had never received treatment, whereas 67% were treated with plasma-derived or recombinant FVIII/FIX concentrates (4% developed inhibitors). desmopressin (DDAVP) was used in 80% of the haemophilia A patients. The response to DDAVP was closely related to the patients' genetic profile, as 60% of non-responders had a mutation in the F8 promoter region. Patients with mild haemophilia may experience a variety of medical problems, sometimes challenging for the physicians, during their lifetime. The HTCs play an important role in the management of these patients, whose diagnosis is often delayed. The HTCs should improve patients' knowledge and consideration of their disease and encourage them to maintain regular contact with their haemophilia care provider.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771207     DOI: 10.1111/j.1365-2516.2011.02617.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  Clinical use of factor VIII and factor IX concentrates.

Authors:  Massimo Morfini; Antonio Coppola; Massimo Franchini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 2.  Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.

Authors:  Giancarlo Castaman; Karin Fijnvandraat
Journal:  Blood       Date:  2014-08-18       Impact factor: 22.113

3.  Plasma exchange and immunosuppressive therapy in a case of mild haemophilia A with inhibitors and a life-threatening lower limb haemorrhage.

Authors:  Chiara Ambaglio; Fabio Lodo; Alice Trinchero; Nicola Ghidelli; Cesare Perotti; Claudia Del Fante; Gabriella Gamba
Journal:  Blood Transfus       Date:  2013-01-02       Impact factor: 3.443

4.  Low-dose continuous infusion of factor VIII in patients with haemophilia A.

Authors:  Tomaž Prelog; Majda Benedik Dolničar; Lidija Kitanovski
Journal:  Blood Transfus       Date:  2015-11-16       Impact factor: 3.443

5.  Burden of mild haemophilia A: Systematic literature review.

Authors:  Flora Peyvandi; Fatemeh Tavakkoli; Diana Frame; Jennifer Quinn; Benjamin Kim; Adebayo Lawal; Mimi C Lee; Wing Y Wong
Journal:  Haemophilia       Date:  2019-07-11       Impact factor: 4.287

6.  The bleeding phenotype in people with nonsevere hemophilia.

Authors:  Fabienne R Kloosterman; Anne-Fleur Zwagemaker; Catherine N Bagot; Erik A M Beckers; Giancarlo Castaman; Marjon H Cnossen; Peter W Collins; Charles Hay; Michel Hof; Britta Laros-van Gorkom; Frank W G Leebeek; Christoph Male; Karina Meijer; Ingrid Pabinger; Susan Shapiro; Michiel Coppens; Karin Fijnvandraat; Samantha C Gouw
Journal:  Blood Adv       Date:  2022-07-26

7.  Desmopressin for bleeding in non-severe hemophilia A: Suboptimal use in a real-world setting.

Authors:  Anne-Fleur Zwagemaker; Fabienne R Kloosterman; Michiel Coppens; Samantha C Gouw; Sara Boyce; Catherine N Bagot; Erik A M Beckers; Paul Brons; Giancarlo Castaman; Jeroen Eikenboom; Shannon Jackson; Marieke J H A Kruip; Frank W G Leebeek; Karina Meijer; Laurens Nieuwenhuizen; Ingrid Pabinger; Karin Fijnvandraat
Journal:  Res Pract Thromb Haemost       Date:  2022-08-31

8.  Hemophilia management: Huge impact of a tiny difference.

Authors:  Fabienne Kloosterman; Anne-Fleur Zwagemaker; Amal Abdi; Samantha Gouw; Giancarlo Castaman; Karin Fijnvandraat
Journal:  Res Pract Thromb Haemost       Date:  2020-02-28

9.  The factor VIII treatment history of non-severe hemophilia A.

Authors:  Amal Abdi; Fabienne R Kloosterman; Corien L Eckhardt; Christoph Male; Giancarlo Castaman; Kathelijn Fischer; Erik A M Beckers; Marieke J H A Kruip; Kathelijne Peerlinck; Maria Elisa Mancuso; Cristina Santoro; Charles R Hay; Helen Platokouki; Johanna G van der Bom; Samantha C Gouw; Karin Fijnvandraat; Dan P Hart
Journal:  J Thromb Haemost       Date:  2020-09-28       Impact factor: 16.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.